Commodore Capital sold 850,000 shares of Nuvalent (NASDAQ:NUVL) for $83.81 million based on quarterly average pricing in its latest SEC filing dated February 17, 2026. The stake’s quarter-end value decreased by $65.75 million, dropping Nuvalent’s share of 13F AUM from 9.26% to 3.68%.

Nuvalent shares were priced at $102.24 on February 17, 2026, up 29% from the previous year, outperforming the S&P 500’s 13% gain. The company develops targeted therapies for cancer, with lead products NVL-520 and NVL-655 in early-stage clinical trials targeting specific genetic mutations in cancers.

Nuvalent, a biotech company specializing in precision cancer therapies, had its stake reduced from 9% to 4% by Commodore Capital in a quarter. The company ended 2025 with $1.4 billion in cash and several upcoming milestones, including FDA acceptance of its NDA for zidesamtinib and an ALK program filing.

Considerations before buying Nuvalent stock include The Motley Fool not listing it among the 10 best stocks to buy now. The Stock Advisor team’s total average return is 904%, significantly outperforming the S&P 500. The latest top 10 list is available with Stock Advisor for individual investors looking to join a community focused on investing.

Read more at Yahoo Finance: Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29%